Shots:

• The open-label P-II study evaluates roflumilast (0.3%, qd). 2 cohorts of patients were enrolled (n=332) incl. Cohort-1 (n=230) who had completed the P-IIb trial @12wk. & participants in Cohort-2 (n=102) were recently enrolled (treatment-naïve)
• The results showed 57.1% achieved an IGA score of clear or almost clear (IGA 0/1) with a median duration of IGA of ≥10mos. (40.1wks). The results were consistent with the (DERMIS) trials, were safe & very well tolerated
• Participants prior treated with roflumilast & roflumilast-naïve, IGA success (35.3% & 37.5%), IGA score (IGA 0/1) @52wk. were 42% & 47.5% while I-IGA success in Cohort-21 (66.7%) with no tachyphylaxis & efficacy was consistent over time, rates of discontinuations due to AEs were low & no evidence of irritation (≥97%)

Ref: Globenewswire | Image: Arcutis

Related News :- Arcutis Reports P-III Trial (INTEGUMENT-2) Results of Roflumilast for the Treatment of Atopic Dermatitis in Adults and Children Aged ≥6 Years